EX-99.2 3 d488989dex992.htm EX-99.2 EX-99.2

Slide 0

Mallinckrodt Strategic Acquisition Ocera Therapeutics, Inc. November 2, 2017 Exhibit 99.2

Slide 1

Forward-looking statements Statements in this document that are not strictly historical, including statements regarding the proposed acquisition of Ocera Therapeutics, the expected timetable for completing the transaction, future financial condition and operating results, economic, business, market opportunity, competitive and/or regulatory factors affecting Mallinckrodt’s and Ocera’s businesses and any other statements regarding events or developments that the companies believe or anticipate will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: General economic conditions and conditions affecting the industries in which Mallinckrodt and Ocera operate; Ocera’s ability to obtain regulatory approval to market its product or the timing of such approval process; The commercial success of Mallinckrodt’s products and of Ocera’s product; The parties’ ability to satisfy the acquisition agreement conditions and complete the Ocera acquisition on the anticipated timeline or at all; Mallinckrodt’s ability to realize anticipated growth, synergies and cost savings from acquisitions (including the Ocera acquisition); Conditions that could necessitate an evaluation of Mallinckrodt's goodwill and/or intangible assets for possible impairment; Changes in laws and regulations; Mallinckrodt’s ability to successfully integrate acquisitions of operations, technology, products and businesses generally and to realize anticipated growth, synergies and cost savings (including with respect to the Ocera acquisition); Mallinckrodt’s and Mallinckrodt’s licensers’ ability to successfully develop or commercialize new products; Mallinckrodt’s and Mallinckrodt’s licensers’ ability to protect intellectual property rights; Mallinckrodt’s ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration; Customer concentration; Mallinckrodt’s reliance on certain individual products that are material to its financial performance; Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations;

Slide 2

Forward-looking statements (continued) The reimbursement practices of a small number of public or private insurers; Pricing pressure on certain of Mallinckrodt's products due to legal changes or changes in insurers' reimbursement practices resulting from recent increased public scrutiny of healthcare and pharmaceutical costs; Limited clinical trial data for H.P. Acthar® Gel; Complex reporting and payment obligations under healthcare rebate programs; Mallinckrodt's ability to navigate price fluctuations; Future changes to U.S. and foreign tax laws; Mallinckrodt’s ability to achieve expected benefits from restructuring activities; Complex manufacturing processes; Competition; Product liability losses and other litigation liability; Ongoing governmental investigations; Material health, safety and environmental liabilities; Retention of key personnel; Conducting business internationally; The effectiveness of information technology infrastructure; and Cybersecurity and data leakage risks. These and other factors are identified and described in more detail in the "Risk Factors" section of Mallinckrodt's Annual Report on Form 10-K for the fiscal year ended September 30, 2016, as well as such sections of Ocera’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt and Ocera do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

Slide 3

Additional Information and Notice to Investors This communication is for informational purposes only and does not constitute an offer to purchase nor a solicitation of an offer to sell any securities of Ocera Therapeutics. The tender offer for the shares of Ocera Therapeutics common stock described in this communication has not yet commenced. The solicitation and offer to purchase shares of Ocera Therapeutics common stock will only be made pursuant to a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. Upon commencement of the tender offer, Mallinckrodt plc and its wholly-owned subsidiaries, MAK LLC and MEH Acquisition Co., will file with the SEC a tender offer statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal, and other related documents. In addition, Ocera will file with the SEC a tender offer solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. These documents will contain important information, including the terms and conditions of the tender offer. Investors and security holders are urged to read each of these documents and any amendments to these documents carefully when they are available prior to making any decisions with respect to the tender offer. Investors and security holders will be able to obtain free copies of these materials (when available) and other documents filed with the SEC through the web site maintained by the SEC at www.sec.gov. Copies of the documents filed by Mallinckrodt plc, MAK LLC and MEH Acquisition Co. with the SEC will also be available free of charge on the Investor Relations section of its website at www.mallinckrodt.com and copies of the documents filed by Ocera with the SEC will be available free of charge on Ocera’s website at ocerainc.com.

Slide 4

Transaction highlights – acquisition of Ocera and OCR-002 (ornithine phenylacetate) developmental asset Assuming a 2017 close, company expects dilution to adjusted diluted earnings per share of approximately $0.25 to $0.35 annually beginning in 2018 Assuming approval of intravenous (IV) and oral formulations, expected peak sales of >$500 million FINANCIAL IMPACT DEAL CONSIDERATION Mallinckrodt to commence cash tender offer to purchase Ocera Therapeutics for $1.52 per share, plus Contingent Value Right; company has global rights to OCR-002 and all related assets Upfront payment: Approximately $42 million; additional payments: up to $75 million dependent on development and sales milestones TIMING Close expected Q4 2017, subject to customary closing conditions Sources: Management projections 1 FDA = Food and Drug Administration 2 EMA = European Medicines Agency DEVELOPMENT STATUS IV formulation (for acute hepatic encephalopathy) now in Phase 2, expected U.S. approval 2022 Oral formulation (for recurrent hepatic encephalopathy) now in Phase 2, expected U.S. approval 2024 Granted U.S. FDA1 Orphan Drug designation and Fast Track status, as well as granted EMA2 Orphan Drug designation

Slide 5

Ocera acquisition builds on Mallinckrodt’s commitment to develop therapies for serious and critical diseases Addresses high unmet need in hepatic encephalopathy Novel ammonia scavenger mechanism IV and oral formulations Strong clinical and commercial alignment with terlipressin OCR-002 Advances MNK emerging focus in hepatic/renal conditions 1 Graft vs Host Disease 2 Deep Partial Thickness 3 Hepatorenal Syndrome 4 Amyotrophic Lateral Sclerosis 5 Full Thickness 6 Diabetic Foot Ulcers 7 Duchenne Muscular Dystrophy 8 Vascular Endothelial Growth Factor 9 Interleukin 10 Toll-like Receptor 11 Acute Pancreatitis Pending close of transaction

Slide 6

Hepatic encephalopathy (HE) is associated with elevated ammonia levels stemming from serious liver disease HE is a continuum of transient, usually reversible neurological and psychiatric dysfunction, associated with elevated ammonia levels2,3 Symptoms range from mildly altered mental status to deep coma, sometimes death1 Goal of HE treatment is aimed at lowering blood ammonia levels3 Once a patient suffers an acute HE episode, prevention of recurrent HE is critical and requires ongoing therapy 1 Clin Liver Dis (2012) Khungar 2 Hepatology (2014) Vilstrup et al 3 NEJM (1997) Riordan et al 0 1 4 3 2 Covert HE Overt HE West Haven Scale1 Elevated Ammonia Levels Drive HE Death Ammonia Carried in the Blood Stream Personality Changes Stupor Coma Disorientation Impaired Motor Skills

Slide 7

OCR-002’s novel mechanism of action helps eliminate ammonia in the bloodstream L-ornithine Glutamate Ammonia PAGN Kidney PAGN Excretion in Urine Metabolic precursor of glutamate, which then combines with ammonia to create glutamine Phenylacetic Acid (PAA) PAA combines with glutamine to form phenylacetylglutamine (PAGN) which is excreted through the kidneys L-ornithine phenylacetate (OCR- 002) Glutamine Carrier of ammonia Ammonia forms when protein is digested by bacteria in intestines; it is then normally converted to urea by liver and eliminated in urine In patients with serious liver disease, elevated ammonia levels passing into the bloodstream from gut can cause HE Company data on file

Slide 8

OCR-002 goal: break vicious cycle of HE 1 Clin Gastroenterology and Hepatology 2015 Patidar et al 2 Int J Gen Med 2015 Saab et al 3 Pharmacotherapy (2010) Neff 4 Clin Gastroenterology and Hepatology 2012 Stepanova et al HE is Chronic, Debilitating and Costly 30-50%: Cirrhosis patients may have HE1 25%: Patients’ first acute episodes occur within five years of HE diagnosis 40-50%: Patients with acute episodes have recurrence within one year; frequency increases with severity2 ~15%: Mortality associated with HE on average; can be greater in more severe patients3 $5-7 billion3,4: Estimated total HE associated costs to U.S. health system Persistent and frequent acute HE has long-term neurocognitive impairment and increases risk for liver transplant1 Overt HE Recurrence or Hospitalization Discharge or Death

Slide 9

OCR-002 has potential to both treat acute HE and prevent recurrent HE, which today is largely untreated Hospitalized ~200K Patients1 1 HCUP, company estimate 2 Clin Liver Dis (2012) 73-89 Khungar et al 3 American Liver Foundation, Clinical Gastroenterology and Hepatology, 2011;9:524-530 Zobair el al 4 Company estimate Used to treat severe HE patients who present in hospital or ICU Goal of treatment is to rapidly lower ammonia levels, improve symptoms and reduce hospitalization No FDA-approved IV treatment to rapidly lower ammonia levels Opportunity for IV to oral OCR-002 transition in hospital IV for acute treatment Used to prevent recurrence of HE in hospital or outpatient setting Goal of treatment is to stabilize ammonia levels once lowered, and prevent rehospitalization Expected to provide step-down and continuity of care with IV Should enable patients to remain stable at home Only small number of at-risk patients are currently treated due to limitations of existing therapies Oral for recurrent treatment INTERNATIONAL MARKET: Worldwide rights to OCR-002 Europe and Japan annual HE market estimates: 150k-200k patients4 AT RISK OF HE ~1.5-2 Million 2 LIVER CIRRHOSIS 5.5 Million 2 CHRONIC LIVER DISEASE 30-35 Million 3

Slide 10

OCR-002 addresses significant unmet medical need and provides commercial opportunity $5.0-7.0 Billion U.S. Market Potential Opportunity1,2 Hospital setting 200k hospitalizations annually3 ~$30,000-$60,000/hospitalization stay including HE treatments1,2 No FDA-approved IV treatment to rapidly lower ammonia levels Opportunity for IV to oral transition in hospital Hospital or outpatient setting Goal to prevent rehospitalization of patients at risk for recurrence ~40-50% recurrence rate within first year of acute event; likelihood of recurrence increases with severity4 Only 50-60% of high-risk patients are receiving current standard of care and fewer stay on therapy due to poor compliance5 1 Pharmacotherapy (2010) Neff 2 Clin Gastroenterology and Hepatology 2012 Stepanova et al 3 HCUP, company estimate 4 Int J Gen Med 2015 Saab et al 5 Company market research IV for acute treatment Oral for recurrent treatment

Slide 11

Rapid improvement in symptoms; reduction in hospital stay OCR-002 is positively differentiated from current treatments for hepatic encephalopathy (HE) OCR-002 Lactulose Rifaximin Formulation IV Oral, nasogastric or enema Oral Method of Action Ammonia scavenger, actively eliminates ammonia in bloodstream and excretes through kidneys Laxative, passively reduces ammonia through bowel movements Antibiotic, passively reduces ammonia by affecting gut flora; excretes ammonia through bowel movements Key Side Effects Difficult to administer in acute setting Poor compliance due to severe diarrhea and GI3 issues Peripheral edema, nausea, dizziness, broad GI issues Restricted for patients with severe liver issues HE Label Acute HE Recurrent HE HE2 Recurrent HE5 Minimal side effects observed to date1 1 Company data on file; Rifaximin label 2 Approved in 1976 3 GI = Gastrointestinal 4 Quintiles/IMS data 5 Approved in 2010 6 Estimated sales from HE indication based on SEC filings, forward looking growth estimates based on analysts’ forecasts Potential Benefits Oral Current Sales ~$40MM4 Generic ~$600MM6 2% CAGR In Development While some drugs are in pre-clinical and Phase 1 development for HE, none are specifically targeting ammonia nor are there IV formulations in development to rapidly lower ammonia levels directly N/A

Slide 12

Mallinckrodt has opportunity to create value by investing and refining OCR-002 clinical program Though STOP HE Phase 2 trial1 did not meet primary endpoint, it achieved secondary endpoints, yielding promising clinical insights Ammonia levels correlated with HE severity and ammonia reduction correlated with clinical improvement OCR-002 lowered ammonia faster and led to faster clinical improvement compared to placebo + standard of care in patients with confirmed hyperammonemia at baseline OCR-002 patients had higher response rate at 48 hours vs. placebo + standard of care; those responders left hospital ~1.5 days earlier OCR‐002 was safe and well‐tolerated Trial design and execution issues contributed to primary endpoint results Inadequate dosing regimen Delays in starting treatment after admission Placebo group heterogeneity (e.g., different standards of care used) Anticipated MNK path forward MNK will invest to establish dosing ranges prior to initiating Phase 3 program Continued engagement with FDA; confirm regulatory pathway; gain approval and launch Company data on file 1 Presentation at The Liver Meeting® the annual meeting of the American Association for the Study of Liver Diseases, held Oct. 20-24. .https://liverlearning.aasld.org/aasld/2017/thelivermeeting/201404/stanley.bukofzer.ocr-002.28ornithine.phenylacetate29.is.a.potent.ammonia.html?f=topic=1572*media=3

Slide 13

Mallinckrodt can maximize value of OCR-002 to address high unmet patient need Addresses high unmet need in acute and recurrent hepatic encephalopathy Enhances portfolio to treat severe and critical diseases related to hepatic and renal conditions, aligns well with terlipressin development asset Broadens specialty brands portfolio with durable, clinically differentiated asset Brings global rights, with initial focus in U.S. Development, regulatory expertise to gain product approval Commercialization and launch support to optimize patient access and clinical impact Clinical and commercial presence in hospital critical care (IV), specialist (oral) settings Enhanced research capabilities and infrastructure (e.g., clinical operations, medical affairs, HEOR1) Operations and manufacturing expertise to enhance formulation development Opportunity to expand to ex-U.S. markets; will explore regulatory pathways for approvals 1 HEOR = Health Economics Outcomes Research OCR-002 can add value to Mallinckrodt: Mallinckrodt can add value to OCR-002:

Slide 14

OCR-002 has robust, durable intellectual property, exclusivity protection Seven years exclusivity from date of first product approval, expected in 2022 ORPHAN DRUG EXCLUSIVITY METHOD OF USE Expires in 2025, with potential for patent term extension1 COMPOSITION OF MATTER Expires in January 2031, with potential for patent term extension1 1 Patent term extension can only be applied to one patent

Slide 15

OCR-002 aligns with MNK strategic vision as patient-centric, innovation driven specialty pharmaceutical growth company focusing on severe and critical conditions In U.S., ~200,000 patients hospitalized with acute HE annually, and 1.5 million at risk for recurrent HE If approved, expected to become first treatment broadly indicated for HE in patients with acute and chronic liver disease ADDRESSES HIGH UNMET NEEDS CLINICALLY DIFFERENTIATED Novel mechanism of action – no other products remove ammonia in bloodstream and excrete through kidneys Only IV formulation to treat acute HE Superior side effect profile compared to current standard of care HIGHLY DURABLE ASSET FDA granted Orphan Drug designation and Fast Track status, as well as Orphan Drug designation by EMA1 Intellectual property and patent estate that extends to at least 2030 WELL ALIGNED WITH TERLIPRESSIN, HEPATIC/RENAL FOCUS Deepens Mallinckrodt’s focus on treating hepatic and renal conditions Strong commercial and clinical synergy potential with terlipressin development asset 1 EMA = European Medicines Agency